SBIR/STTR Research Award

Platelet Production in a Pulmonary-based Microfluidic Reactor

Award identifier 3b6d3cbe76bdd82ae13284bd52efb7f7a64b799d34588e44dcc0a6bb0a039a91Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$308,559

Program and phase

SBIR · Phase I

Award year

2020

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Fluxion Biosciences Inc.
Proposal award date
2020-06-01
Contract end date
2020-11-30
UEI
QXRFWL41N789
Solicitation number
PA18-574
Topic code
NHLBI

Research abstract

ABSTRACT Platelet transfusions are used to treat deficiencies in platelet number and/or function that is seen in multiple clinical settings such as cancer and post trauma. Given changing demographics and an increasing reliance on platelet transfusion in modern medicine, its is likely that donor-derived platelets to provide this care may prove inadequate in the near future. The generation of large numbers of physiologically viable platelets in-vitro is intended to provide a new treatment option for such patients with platelet deficies. Starting with mega- karyocytes (Megs), platelet release (thrombopoiesis) is driven by shear forces typically found in the vasculatures. Previous approaches were aimed at mimicking platelet production in the bone marrow as Megs emerge from the intramedullary space into the blood stream, but new research points to significant platelet production by Megs embedded in the lung. This proposal is aimed at taking advantage of this discovery to improve both our understanding of thrombopoiesis and our ability to produce platelets in vitro focused on mimicking the particular properties of the pulmonary microvasculature. There are four aims in this application: Aim 1: Produce and test devices recapitulating the pulmonary vascular bed. Several different will be manufactured to entrap Megs and allow thrombopoiesis to occur. Aim 2: Design and test a system for platelet production under lung-mimetic mechanical strain. We will use flexible microfluidic layers will b. Aim 3: Design and test a system for temporal control of O2 concentration within the reactor. Switching from a low to high O2 partial will be achieved to replicated physiological changes in the lung. Aim 4: Optimize the combined effects of lung model parameters and test platelet functional performance. The final microfluidic devices using all of the optimal parameter determined will be tested by infusions of Megs and measurement of the efficacy to produce platelet-like particles that physically and functionally match that of freshly-drawn donor-derived platelets. Phase I research is intended to validate a consumable compatible with existing controllers that can we used widely to study platelet production lung microenvironment by controlling cappillary, shear forces, defomation of capillary bed and gas concentration. If successful, a scale-up to a clinically feasible platelet production reactor will be attepted in Phase II. This work represents a collaboration between a bioengineering company that has been supplying microfluidic research systems for the study of platelet function and a laboratory that are domain experts in the treatment of platelet disorders.Narrative Platelet deficiency is often treated via transfusions from heathy donors, leading to challenges related to limited supply and disease transmission risks. While our ability to generate large number of platelets outside the body has seen significant developments, it is not yet efficient enough to be deployed in the clinic. If successful, this proposal will improve in-vitro platelet production systems utilizing the discovery of platelet production in the lung, and lead to improved treatment options for patients currently requiring platelet transfusions.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

8 SBIR/STTR records share this UEI (2005–2020). Reported award amounts total $3,826,361. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.